Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 12.54B 10.96B 10.14B 9.46B 17.76B 1,185B 17.89B 120B 46.87B 583B 47.09B 46.07B 2,024B P/E 2026 *
-21x
P/E 2027 * -58.8x
Enterprise Value 12.32B 10.77B 9.96B 9.3B 17.45B 1,165B 17.58B 118B 46.05B 573B 46.27B 45.26B 1,989B EV / Sales 2026 *
13.8x
EV / Sales 2027 * 8.31x
Free-Float
99.08%
Yield 2026 *
-
Yield 2027 * -
1 day+1.74%
1 week+3.56%
Current month+795.77%
1 month+795.77%
3 months+795.77%
6 months+795.77%
Current year+795.77%
1 week 64.4
Extreme 64.4
65.66
1 month 62.42
Extreme 62.42
65.66
Current year 62.42
Extreme 62.42
65.66
1 year 62.42
Extreme 62.42
65.66
3 years 62.42
Extreme 62.42
65.66
5 years 62.42
Extreme 62.42
65.66
10 years 62.42
Extreme 62.42
65.66
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Change 5-day change 1-year change 3-year change Capi.($)
+1.74%+3.56% - - 12.54B
+0.34%+1.09%-10.67%-5.05% 43.24B
+1.73%+3.59%+318.08%+564.04% 35.25B
+0.61%+1.34%+10.00%+46.20% 30.22B
+0.02%-5.93%+8.45%-21.44% 28.01B
-1.06%-3.71%+9.08%+19.56% 24.08B
-1.23%+2.11% - - 14.16B
-0.99%-2.53%+47.29%+102.88% 13.01B
+1.54%+0.16%+6.69%+8.89% 12.7B
-3.61%-4.73%-3.93%-38.09% 10.78B
Average -0.09%-1.08%+48.12%+84.62% 23.49B
Weighted average by Cap. +0.18%-0.60%+61.67%+111.37%

Financials

2026 *2027 *
Net sales 890M 778M 719M 671M 1.26B 84.1B 1.27B 8.55B 3.33B 41.35B 3.34B 3.27B 144B 1.49B 1.31B 1.21B 1.13B 2.12B 141B 2.13B 14.35B 5.58B 69.4B 5.61B 5.49B 241B
Net income -595M -520M -481M -449M -843M -56.24B -849M -5.72B -2.22B -27.65B -2.23B -2.19B -96.06B -216M -189M -174M -163M -306M -20.4B -308M -2.07B -807M -10.03B -810M -793M -34.84B
Net Debt -219M -191M -177M -165M -310M -20.71B -313M -2.1B -819M -10.18B -823M -805M -35.37B -122M -106M -98.48M -91.91M -173M -11.51B -174M -1.17B -455M -5.66B -457M -448M -19.67B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-06-22 65.66 +1.74% 0
26-06-18 64.54 -0.25% 0
26-06-17 64.70 +2.89% 5
26-06-16 62.88 -0.82% 0
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
75.89USD
Average target price
104.91USD
Spread / Average Target
+38.24%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!